<![CDATA[ Media - Aromics]]> <![CDATA[ Media - Aromics]]> http://aromics.es/rss/en/newsroom/media <![CDATA[TOP 2021 companies: the CEO of AROMICS among the most outstanding professionals in business]]> Detail of the short interview with Dr. Carmen Plasencia, CEO and co-founder of AROMICS. The interview published last June 27, 2021 in the weekly supplement of Empresa of the ABC newspaper, allows readers to understand the main keys of the developments made in this small biotech from Barcelona, which are mainly focused on the progress towards the clinic of a new antitumor to combat a complex and resistant cancer: malignant mesothelioma. Also known as asbestos cancer, due to its direct relationship with the inhalation of fibers of this material widely used in construction until 2002.  The development of Aromics has received support from the European Union's Horizon 2020 program. For more information, see the Bermes Project website

 

]]> <![CDATA[Biotechnology and COVID impact_ AROMICS]]> Interview Dr. Carme Plasencia about the impact of COVID-19 on the projects developed by AROMICS.

]]> <![CDATA[Using ‘Omics’ to Develop Treatments for Drug-Resistant Cancer]]> Labiotech.eu, the leading digital media covering the European Biotech industry with over 150,000 monthly visitors, has selected AROMICS as one of the biotechs in Europe leading with OMIC technologies and its application to drug discovery and development.

]]> <![CDATA[Copying Asbestos Legacy]]> The European biotechnology Journal in its Spring edition, echoes our work in malignant mesothelioma, a rare ang aggressive cancer directly linked to asbestos exposure.

]]> <![CDATA[AROMICS develops a novel therapy for malignant mesothelioma]]> AROMICS is developing a novel therapy for the treatment of rare and highly refractory cancers like malignant mesothelioma, an asbestos-related cancer.

European Commission through its SME instrument at Horizon 2020 program is supporting the company in the development.

]]> <![CDATA[AROMICS receives 1 Million Euros to advance in its therapy for cancer]]> The European Commission has allocated, through the H2020-EIC-SMEInst-2018-2020-Phase 2 program,  a total of 1,085.659€ to the BERMES project of Aromics, the objective of which is to complete the regulatory pre-clinical stage in order to begin studies in humans of the drug NAX035 for malignant mesothelioma, an aggressive and highly resistant cancer linked to asbestos exposure.

 

]]> <![CDATA[AROMICS receives 1 Million Euros to advance in its therapy for cancer]]> El mundo

Malignant Mesothelioma is an aggressive, poor prognosis and highly refractory cancer. It is also known as the "asbestos cancer", as this mineral widely used at the industrial settings over the past century, is the main origin of the tumour. The published new established an important milestone for AROMICS. The company has received EU H2020 funding for advancing in a new therapy to treat this devastating cancer.  

]]> <![CDATA[AMMIC: New platform for Catalan companies and organizations accelerates drug R&D for minority diseases]]> Acceleradora en Malalties Minoritàries de Catalunya (AMMIC) is part of the RIS3CAT community coordinated by Biocat. It is led by IUCT and other members include VHIR, Esteve, Aromics, BCN Peptides, Minoryx, Aniling and Qgenomics

After its first year of work, the AMMIC project has seen its first scientific results, including the launch of a phase II/III study in Adrenoleukodystrophy, the preclinical assessment with animal models of the efficacy of three new candidate molecules to treat Malignant pleural mesothelioma, Pediatric Rhabdomyosarcoma and Myotonic dystrophy type 1.

Follow the new here

]]> <![CDATA[Asbestos and cancer]]> Malignant Mesothelioma is an aggresive, poor prognosis and highly refractory cancer. It is also known as the "asbestos cancer", as this mineral widely used at the industrial settings over the past century, is the main origin of the tumor.

The published new established an important milestone: first sentence of a judge admiting the damage induced by asbestos to neighbours that simply lived closed to the area of influence of an asbestos' manufacture industry.

 

]]>